Having trouble accessing articles? Reset your cache.

Dapagliflozin: Phase III data

A double-blind, international Phase III trial in 597 patients with inadequately controlled Type II diabetes showed that all 3 doses of oral dapagliflozin as an add-on to glimepiride met the primary endpoint of significantly reducing HbA1c from

Read the full 377 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE